These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Effect of short-term therapy with recombinant human growth hormone (GH) on metabolic parameters and preclinical atherosclerotic markers in hypopituitary patients with growth hormone deficiency. Benedini S; Dalle Carbonare L; Albiger N; Scanarini M; Bilora F; Petrobelli F; Giannini S; Mantero F; Scaroni C Horm Metab Res; 2006 Jan; 38(1):16-21. PubMed ID: 16477535 [TBL] [Abstract][Full Text] [Related]
25. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Yuen KC; Frystyk J; White DK; Twickler TB; Koppeschaar HP; Harris PE; Fryklund L; Murgatroyd PR; Dunger DB Clin Endocrinol (Oxf); 2005 Oct; 63(4):428-36. PubMed ID: 16181235 [TBL] [Abstract][Full Text] [Related]
26. Insulin-like growth factor-I, cognition and brain aging. van Dam PS; Aleman A Eur J Pharmacol; 2004 Apr; 490(1-3):87-95. PubMed ID: 15094076 [TBL] [Abstract][Full Text] [Related]
27. Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption. Svensson J; Mattsson A; Rosén T; Wirén L; Johannsson G; Bengtsson BA; Koltowska Häggström M; Growth Horm IGF Res; 2004 Jun; 14(3):207-15. PubMed ID: 15125882 [TBL] [Abstract][Full Text] [Related]
28. Effects of growth hormone and insulin-like growth factor-1 on cardiac hypertrophy of hypertensive patients. Sesti G; Sciacqua A; Scozzafava A; Vatrano M; Angotti E; Ruberto C; Santillo E; Parlato G; Perticone F J Hypertens; 2007 Feb; 25(2):471-7. PubMed ID: 17211256 [TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD). Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776 [TBL] [Abstract][Full Text] [Related]
30. The IGF-I response to very low rhGH doses is preserved in human aging. Lanfranco F; Ceda GP; Ramunni J; Aimaretti G; Gianotti L; Di Vito L; Arvat E; Camanni F; Ghigo E J Endocrinol Invest; 1999; 22(10 Suppl):59-60. PubMed ID: 10727047 [No Abstract] [Full Text] [Related]
31. Treatment of growth hormone deficiency syndrome in adults. De Feo P; Lucidi P; Santeusanio F Diabetes Nutr Metab; 1999 Oct; 12(5):336-9. PubMed ID: 10741348 [No Abstract] [Full Text] [Related]
32. [Recommendations for the indications for growth hormone substitution in adult age groups. Working group for pituitary gland and pituitary tumors of the German Society for Endocrinology]. Oertel H; Strasburger CJ; Kann P; Quabbe HJ Dtsch Med Wochenschr; 1998 Jul; 123(28-29):883-6. PubMed ID: 9693660 [No Abstract] [Full Text] [Related]
33. [Diagnostic criteria for the indication of growth hormone substitution in adults. The Hypophysis and Hypophyseal Tumor Working Group of the German Society for Endocrinology]. Strasburger CJ; Schopohl J; Kann P; Oertel H Dtsch Med Wochenschr; 1997 Jul; 122(27):861-3. PubMed ID: 9280697 [No Abstract] [Full Text] [Related]
34. [Biologically inactive growth hormone]. Bozzola M; Buzi F; De Sanctis C; De Sanctis V; Radetti G; Rigon F; Tatò L; Tonini G; Bernasconi S; Bona G Minerva Endocrinol; 1999 Jun; 24(2):83-5. PubMed ID: 10941428 [No Abstract] [Full Text] [Related]
35. Should we treat the somatopause? Hoffman AR; Ceda GP J Endocrinol Invest; 1999; 22(10 Suppl):4-6. PubMed ID: 10727025 [No Abstract] [Full Text] [Related]
36. Frailty and the somatopause. Martin F Growth Horm IGF Res; 1999 Feb; 9(1):3-10. PubMed ID: 10207502 [No Abstract] [Full Text] [Related]
37. GH and the heart: potential therapeutic use. Isgaard J; Bengtsson BA Growth Horm IGF Res; 2000 Dec; 10(6):295-6. PubMed ID: 11161959 [No Abstract] [Full Text] [Related]